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Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a 
heterogeneous group of syndromes characterised by small-vessel inflammation and 
involvement of pathogenic autoantibodies. In patients with granulomatosis with 
polyangiitis (GPA) the ANCA are mainly directed against proteinase 3 (PR3) and in 
patients with microscopic polyangiitis (MPA) against myeloperoxidase (MPO) [1]. Both 
PR3 and MPO are localised in the azurophilic granules of neutrophils and the granules 
of monocytes [2, 3]. 
AAV patients generally achieve remission through the use of immunosuppressive 
treatment. Long-term immunosuppressive treatment is associated with toxicity, and 
requires that treatment is tapered in patients. AAV patients suffer from frequent disease 
relapses, often during tapering or after discontinuation of treatment [4]. Each relapse is 
associated with the risk of cumulative damage [5]. For example, every renal relapse is 
associated with a decrease in estimated glomerular filtration rate, a measure of kidney 
function [6]. Therefore, one of the main clinical challenges in AAV is finding accurate 
methods to predict disease relapse. If biomarkers for relapse are identified this could 
allow for timely intervention in patients that are about to relapse. 
Many types of immune cells are involved in AAV disease pathogenesis, including 
neutrophils, B cells and T cells. Recently the role of B cells has received more interest. 
B cells can exert both regulatory and effector functions. Changes in the balance of 
these functions may influence the risk for relapse in patients. Therefore, in this thesis, 
we investigated the B cell phenotype and function in GPA patients and related this to 
relapse risk.  
ANCA as a potential biomarker for relapse
Several observations suggest that ANCA play an essential role in the pathophysiology 
of AAV. As discussed in chapter 2, ANCA are capable of activating neutrophils in 
vitro [7], resulting in the formation of neutrophil extracellular traps [8] and eventually 
in endothelial cell injury [9]. Moreover, several animal models have demonstrated the 
pathogenic role of MPO-ANCA in the development of an MPA phenotype [10, 11]. 
ANCA are generally measured systemically in patient serum by indirect 
immunofluorescence and the resulting ANCA titer has often been related to disease 
activity and the risk for relapse. The overall conclusion has been that monitoring ANCA 
titers alone is insufficient to guide decisions on treatment [12–14]. In chapter 3 we 
describe an alternative method to detect the production of PR3-ANCA in GPA patients. 
A combination of exogenous (CpG-oligondeoxynucleotides) and endogenous (B cell 
activating factor (BAFF) and interleukin (IL)21) factors could induce production of ANCA 
in isolated peripheral blood mononuclear cells (PBMCs) from a substantial proportion 
of GPA patients. These factors synergised in the induction of B cell proliferation and 
induced formation of plasma cells. Moreover, the use of CpG resulted in upregulation 























production was even detected when PBMC were cultured without stimulation. This 
was seen in a smaller number of patients, but suggests an increased activation status 
of autoantibody producing cells or their precursors.
The ANCA titer is a reflection of accumulated autoantibodies in serum, while an in 
vitro system may reflect the current capacity for ANCA production better and could 
be more accurate for relapse prediction. In chapter 4 we investigated both the ANCA 
titer and in vitro ANCA production in relation to relapse in PR3-ANCA positive GPA 
patients. Eighty-four PR3-ANCA positive GPA patients were prospectively monitored 
for up to two years and 16 relapses were detected during this period. On group level 
we did observe an increase in ANCA titer prior to relapse, although this increase 
was not present in every individual patient. Regarding in vitro ANCA production, 
a number of patients demonstrated a very clear increase before relapse, and this 
was particularly visible in unstimulated cell culture samples. However, this increase 
in in vitro PR3-ANCA before relapse was not significant on group level. Based on 
these data, we can conclude that monitoring in vitro ANCA production cannot 
identify all GPA patients that are about to relapse and this method does not appear 
more accurate for relapse prediction than measuring ANCA titers. Recently it was 
described that the predictive value of ANCA titers was increased when applied 
only to AAV patients that presented with renal involvement [15]. Moreover, newer-
generation methods exist for ANCA measurements in serum that may result in 
more accurate estimations of ANCA levels [16]. Multiple variants of enzyme-linked 
immunosorbent assays (ELISA) have become available, for example the anchor ELISA 
which uses a technique to immobilise PR3 on the ELISA plate surface by employing 
an anchor molecule as a bridge. This technique demonstrated superior sensitivity for 
the detection of PR3 antibodies in GPA patients [17]. Another example is the Phadia 
ImmunoCAP system applied in chapter 4 for cell culture supernatants. In order to 
fully establish the value of (in vitro) ANCA in prediction of relapse in AAV larger 
prospective studies need to be done in order to detect more relapses. Including 
more patients will also allow for specific sub analyses based on clinical parameters, 
and may potentially identify patient groups in which ANCA measurements are more 
applicable for relapse prediction. 
A final point to consider with regard to monitoring ANCA production is that not 
all ANCA may be equally pathogenic. As discussed in chapter 2, one study found 
that for MPO-ANCA epitope specificity appeared to define pathogenicity [18]. Low 
levels of ANCA have been detected in healthy individuals [19], and MPO-ANCA from 
healthy individuals had epitope specificities that were different from those in patients. 
Interestingly, ANCA were also detected in patients that were previously thought to be 
ANCA negative. Further characterisation demonstrated that ANCA in these patients 
were directed at the same epitope that was associated with active disease in MPA 
patients [18]. These data do need to be confirmed by further studies and similar analysis 























The level of glycosylation is another mechanism that could affect pathogenicity of 
antibodies [20]. The IgG subclasses from active GPA patients are hypoglycosylated 
compared to controls, and a positive correlation has been detected for anti-PR3 specific 
IgG1 galactosylation and the time to remission [21]. Moreover, the ratio between levels 
of sialylated anti-PR3 antibodies and levels of total anti-PR3 antibodies was significantly 
lower in patients with active disease than patients in remission. Desialylation of IgG 
antibodies in GPA patients resulted in a significantly stronger oxidative burst of 
neutrophils than nondesialylated IgG antibodies [22]. 
Collectively, studies defining specific molecular features of the autoantibodies allowing 
for distinguishing pathogenic ANCA from non-pathogenic ANCA may eventually 
increase the value of ANCA measurements for relapse prediction.
B cell phenotype and cytokine production in 
relapsing GPA patients
B cells are clearly involved in the pathogenesis of AAV, as they are the precursors of the 
plasma cells that produce ANCA. However, B cells can exert multiple other functions 
as well, including antigen presentation and production of a variety of pro- and anti-
inflammatory cytokines [23, 24]. As such they may be involved in other pathogenic 
processes as well as in regulation of the immune response. Proinflammatory cytokines 
including tumour necrosis factor (TNF)α and interferon (IFN)γ can for example promote 
T helper-1 (Th1) responses [25, 26], while anti-inflammatory cytokines can suppress the 
immune response. One example of the latter is IL10, known as the signature cytokine for 
the regulatory B cell (Breg) population. Bregs have been described to inhibit production 
of proinflammatory cytokines from monocytes and effector Th cells and support the 
differentiation of regulatory T cells [27].
Based on its surface markers B cells can be divided into several subsets. While 
alterations of B cell subsets have been described in multiple autoimmune diseases, 
it remains unknown whether a specific B cell subset profile is associated with disease 
relapse. Memory B cells can be identified by their expression of CD27, while naive B 
cells lack CD27 [28] and transitional B cells have high expression of CD38 [29]. Multiple 
suggestions have been made to identify Bregs in the circulation based on surface 
marker expression, including CD24highCD38high [30] and CD24highCD27+ B cells [31]. In 
AAV patients, a decreased proportion of memory and CD24highCD27+ B cells and an 
increased percentage of naive B cells was observed compared to healthy controls [32]. 
In chapter 4 we confirm these differences in a larger cohort of GPA patients. What 
we observed further is that patients about to relapse deviate the most from healthy 
controls, with even lower percentages of memory and CD24highCD27+ and higher 
percentages of naive B cells compared to non-relapsing patients. It is unclear whether 
the decrease in CD24highCD27+ B cells is indicative of decreased B cell regulation or 























We observed in chapter 5 that GPA patients have increased levels of serum CCL19 
compared to healthy controls. CCL19 is a trafficking chemokine that has particularly 
been associated with memory B cell migration [33]. Increased migration of memory 
B cells in GPA patients could explain their decreased presence in the periphery and 
the further decrease in the percentage of memory B cells seen before relapse. To 
fully prove this, tissue biopsy studies are needed to analyse the presence of different 
B cell subsets, including memory B cells, in remission patients and compare this to 
active disease sites, such as the kidneys or lungs. Moreover, we analysed total CD27+ 
memory B cells in chapter 4, a subset that can be further subdivided in class-switched 
and non-switched memory B cells. It would be interesting to analyse differences within 
the memory B cell distribution and determine whether this can improve its value for 
relapse prediction in GPA.
The balance between pro- and anti-inflammatory cytokine production by B cells could 
also affect the risk for relapse in patients with GPA. Therefore, the B cell cytokine 
production profile was assessed in chapter 5 in relapsing patients, non-relapsing 
patients and healthy controls. Significantly fewer B cells from GPA patients were 
producing TNFα compared to controls, which was especially visible in patients before 
relapse. TNFα production correlated positively with other proinflammatory cytokines, 
IL2 and IFNγ, and the presence of memory B cells in vitro. As such, the reduced 
presence of memory B cells in the circulation may explain the decreased percentage 
of TNFα producing B cells. At the moment, data regarding proinflammatory cytokine 
production by B cells in humans is scarce. It would be interesting to determine whether 
other autoimmune diseases where memory B cells were found decreased compared 
to controls, for instance Sjögren’s syndrome [34], display similar differences in effector 
B cell cytokine production as we found for GPA. Moreover, samples from GPA patients 
with active disease should be analysed to determine whether circulating memory B cells 
and TNFα producing B cells decrease further upon relapse. 
The association between TNFα production and memory B cells has been described 
previously. In rheumatoid arthritis (RA) patients TNFα production was threefold 
greater from memory B cells than from naive B cells [35]. From multiple sclerosis (MS) 
patients and controls, naive and memory B cells were sorted and stimulated using 
CD40 engagement and/or B cell receptor (BCR) cross-linking. Proliferation rates upon 
stimulation were similar in the B cell subsets, but cytokine profiles differed. Memory 
B cells produced high levels of TNFα upon dual stimulation while naive B cells produced 
IL10 mainly with CD40 engagement alone [36]. These data suggest the existence of 























Regulatory B cells and interleukin-10 
production in GPA. 
In order to investigate the regulatory capacity of B cells, we also determined IL10 
production in chapter 5. No association was observed with this anti-inflammatory 
cytokine and naive B cells in our analyses, nor did we find differences for IL10 
production in B cells from healthy controls, relapsing patients and non-relapsing 
patients. However, in individual patients prior to relapse IL10 production did decrease 
significantly, indicating a certain decrease of regulatory capacity may occur prior to 
relapse. Previous studies have been in disagreement with regard to differences in IL10 
production in AAV patients and HC [32, 37, 38]. We can conclude from our results that 
the potential for IL10 production does not appear to be hampered in GPA patients when 
B cells are stimulated with the Toll-like receptor (TLR) 9 ligand CpG-ODN. However, it 
can be argued that CpG stimulation does not sufficiently simulate the in vivo situation. 
Other methods used to induce IL10 production in B cells include CD40 signalling, used 
as a mimic for receiving help from activated T cells in the absence of specific B cell 
antigens [36]. Addition of CD40L could also further enhance the production of IL10 by 
TLR stimulated B cells [31]. It is possible that different types of stimulation induce IL10 
production through different pathways and in different B cell populations. To determine 
this, multiple methods of IL10 induction should be directly compared and associated 
with a wide array of described B cell surface markers. It also appears that a certain 
degree of plasticity exists with regard to IL10 production in B cells. This is underscored 
by a mouse model using IL10 reporter mice to track regulatory B cell induction and fate. 
In this study it was found that regulatory B cells only transiently expressed IL10 prior 
to terminal differentiation into antibody-secreting plasmablasts and plasma cells [39].
It would be ideal if the Breg could be identified by surface markers, circumventing 
the need for ex vivo stimulation. However, at the moment the Breg remains an elusive 
cell. Different surface markers have been associated with the regulatory phenotype. 
Perhaps the best known phenotypes are the aforementioned CD24highCD38high and 
CD24highCD27+ B cell subsets. An alternatively proposed marker is CD5. In patients 
with active AAV lower percentages of CD5+ B cells were detected, while patients in 
remission were similar to controls [40]. CD5+ B cells correlated positively with the 
CD24highCD38high subset and were shown to be predictive of relapse after treatment 
with rituximab [41]. Furthermore, CD5+ B cells have been shown to produce more IL10 
than CD5- B cells after BCR activation and introduction of CD5 by transfection using 
vectors encoding the full-length CD5 molecule into a CD5- human B cell line activated 
synthesis of IL10 mRNA [42]. CD5+ B cells also express higher levels of the death 
inducing ligand FasL than CD5- B cells, and it has been suggested that these B cells 
may have a specialised regulatory function as so-called killer B cells [43]. 
In addition, plasmablasts have been ascribed with regulatory function. In an experimental 























identified, and the EAE phenotype was exacerbated when plasmablasts were lacking. 
In the same study human plasmablasts, particularly CD27int plasmablasts derived from 
naive B cells, were described to preferentially secrete IL10 [44]. A second study found IL10 
production enriched in both CD24highCD27+ B cells and CD27highCD38high plasmablasts [45]. 
Recently the CD24highCD38high B cells were characterised in-depth, using multicolour 
flow cytometry in combination with bioinformatics and functional studies. This analysis 
provided evidence for the existence of different CD24highCD38high transitional B cell subsets 
with unique phenotypic and regulatory functional profiles suggesting that different 
regulatory defects in different autoimmune diseases may be due to altered distributions 
of these subsets. CD27+ transitional B cells could suppress production of proinflammatory 
cytokines and were demonstrated to produce high levels of IL10. However, production of 
IL10 was not restricted to any specific B cell subset [46]. Others have similarly suggested 
that IL10 producing B cells are diffusely scattered throughout the B cell lineage, and are 
not confined to either the memory (IgD+CD27+) or the transitional (CD24high CD38high) B cell 
compartment [47]. We also did not find a positive association between production of IL10 
by B cells and CD24highCD38high, CD24highCD27+ or CD5+ B cells in chapter 5.
To complicate matters further, IL10 independent Breg mechanisms have been described 
[48]. Mice with a B cell deficiency had a significant reduction in the number of peripheral 
regulatory T cells, which was restored by adoptive transfer of B cells. For this result 
glucocorticoid-induced TNF ligand, but not IL10 expression, by B cells was required 
[49]. Signalling through the inhibitory receptor programmed death receptor-1 ( PD-1) 
can inhibit population expansion, cytokine production and cytolytic function of T cells 
[50]. B cells expressing high levels of the ligand PD-L1 can therefore suppress humoral 
responses and antibody production by attenuating T cell activation [51]. Finally, other 
cytokines are important in the negative regulation of immunity, for example IL35. Mice 
with IL35-deficient B cells were unable to recover from EAE. In this model, IL35 was 
mainly produced by CD138+ plasma cells [52]. 
In conclusion, regulatory B cells remain difficult to analyse, as different subsets based 
on differential expression of surface markers have been indicated to produce IL10 
and B cells exhibit regulatory functions by multiple mechanisms. It is possible that no 
specific IL10 producing regulatory B cell subset exists, and IL10 production is induced 
in different B cells through presence of environmental factors.
Associations between ANCA and cytokine 
production
Production of pro- and anti-inflammatory cytokines could influence the production of 
autoantibodies in vitro. In chapter 6 we explored cytokine production in cell culture 
supernatants from GPA patient samples with and without in vitro ANCA production 
and controls. This demonstrated that in vitro ANCA production correlated with several 























Moreover, we observed that when in vitro ANCA production increased in individual 
patients, levels of IL10 in these culture supernatants increased concomitantly. These 
data suggest that in samples from certain patients a higher level of plasma cells 
formation and survival occurs, resulting in more PR3-ANCA production. To confirm 
this, plasma cell formation should be investigated at different time points during the 
course of an in vitro ANCA culture. Furthermore, it would be interesting to measure 
circulating plasma cells in GPA patients, based on CD138+ expression, and associate 
this with ANCA production in vitro. In RA patients the production of anti-citrullinated 
protein antibodies (ACPA) in vitro was found to be similar when CD20+ cells were 
depleted, indicating that production ex vivo was dependent on plasmablasts and cells 
from the circulation [53].
Conversely, when IL10 was added exogenously to cell cultures it could inhibit the 
production of PR3-ANCA (chapter 6). This inhibitory effect was strongest when 
IL10 was added directly at the start of cell cultures. As mentioned, aside from its 
regulatory functions IL10 is known as a plasma cell differentiation and survival factor 
[54]. Therefore, the effect of IL10 in this setting may be dependent on both timing and 
the cell composition in vitro. When IL10 is present prior to plasma cell formation it can 
exert a regulatory function, while IL10 added at a later stage may act as a plasma cell 
survival factor. IL10 and other cytokines involved in plasma cell formation could be 
added during different stages of cell cultures to examine their effect on both plasma 
cell formation and ANCA production.
B cell targeted treatment strategies.
The importance of B cells in autoimmune pathogenesis is underscored by the development 
of several therapeutic options that target B cells. In Figure 1, several treatment options 
and their B cell related targets are visualised. The anti-CD20 monoclonal antibody 
rituximab has been investigated and approved as an alternative induction therapy for 
AAV. This B cell depleting treatment was not inferior to cyclophosphamide for inducing 
remission [55, 56]. Moreover, treatment with rituximab has shown promise as maintenance 
therapy, one study found fewer relapses with rituximab than azathioprine while adverse 
event rates were similar [57]. However, rituximab treatment has also been associated 
with increased risk of adverse effects, in particular persistent hypogammaglobulinemia 
which predisposes patients to recurrent infections [58].
There is also interest in strategies aimed at BAFF and a proliferation inducing ligand 
(APRIL). BAFF and APRIL are TNF family members, with roles in modulating lymphocyte 
survival, activation and differentiation [59]. The rationale for such a strategy is that 
autoreactive B cells appear to have a heightened dependency on BAFF, and excessive 
BAFF production can rescue autoreactive B cells from peripheral deletion [60]. 
Moreover, in patients with GPA elevated serum levels of BAFF and APRIL have been 























Figure 1. B cell targets. Treatment strategies are aimed at different targets expressed on B cells, 
or targets with receptors present on B cells. Rituximab targets CD20, present on all stages of B cell 
development except the early pro-B cells and plasma blasts and cells. Belimumab, tabalumab and 
atacicept target the TNF cytokine family members B cell activating factor (BAFF) and a proliferation 
inducing ligand (APRIL). B cells have several receptors for these activating cytokines, BAFF receptor, 
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B cell 
maturation antigen (BCMA). Abatacept inhibits costimulatory signalling. Tocilizumab is a monoclonal 
antibody aimed at the interleukin (IL)6 receptor present on B cells, inhibiting IL6 binding to IL6R. Finally, 
ShK-186 targets the Kv1.3 potassium channel, particularly expressed by switched memory B cells.
proximity of the autoantigens, BAFF and APRIL [63]. Treatment with rituximab leads 
to heightened levels of BAFF [64] and may favour autoreactive B cells. Therefore, 
neutralisation of BAFF could be particularly beneficial in rituximab treated patients. 
The anti-BAFF monoclonal antibody belimumab has been approved for treatment 
of systemic lupus erythomatosis (SLE), resulting in improved disease activity scores 
[65, 66]. In addition to belimumab, other BAFF (and APRIL) neutralising therapeutic 
agents have been developed, such as tabalumab [67] and atacicept [68]. While targeting 
BAFF profoundly reduced numbers of naive B cells, it had a markedly smaller effect 
on memory B cells and long-lived plasma cells [69]. Similarly, memory B cells did not 
require APRIL for survival or function [70]. This suggests that essential B cell populations 
involved in autoimmune pathology may be missed with BAFF/APRIL targeted therapy. 
Abatacept is a fusion protein of cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4)-Ig and the immunoglobulin Fc region, which inhibits costimulatory signalling and 
consequently inhibits the activation of T cells. In an open-label study in GPA patients, 
addition of abatacept was well tolerated and associated with high frequency of disease 
remission and prednisone discontinuation [71]. Treatment with abatacept in RA also 























of Ig and decreasing titers of ACPA and rheumatoid factor (RF). Finally, decreased 
percentages of post-switch memory B cells were found after abatacept treatment [72]. 
IL6 receptor inhibition by tocilizumab also affects the B cell compartment. In an open-
label study in RA a significantly reduced frequency of memory B cells and serum 
immunoglobulin levels was detected [73]. Moreover, expression of intracellular TGFβ 
in CD25high B cells was significantly increased in samples from patients treated with 
tocilizumab for 3 months, while expression of the activation marker CD69 was reduced 
[74]. As TGFβ is another immune-regulatory cytokine expressed by B cells, this suggests 
that tocilizumab may influence the B cell regulatory capacity. In patients with RA and 
to a lesser extent in patients with giant cell arteritis, tocilizumab has demonstrated 
benefit [75, 76]. Clinical trials are needed to determine the efficacy of these types of 
treatment in patients with AAV.
Considering the multiple regulatory mechanisms associated with B cells it remains 
a question whether indiscriminately targeting B cells, as rituximab does, is the best 
treatment option. Specifically targeting the effector B cells would leave regulatory 
mechanisms intact. The voltage-gated potassium channel Kv1.3 is highly present on 
IgD-CD27+ switched memory B cells, while naive and IgD+CD27+ B cells express low 
levels of this specific channel [77]. Switched memory B cells have been described to 
be primarily responsible for proinflammatory cytokine production [36], and they can 
differentiate into (auto)antibody producing plasma cells [78]. The effect of Kv1.3 channel 
blockade has mainly been described in T cells, as this channel is also highly expressed 
by effector memory T cells upon activation [79]. Specific Kv1.3 inhibitors have been 
effective in several animal models of immune-mediated inflammation, including anti-
glomerular basement membrane glomerulonephritis [80]. 
In chapter 7 we examined the effect of Kv1.3 channel blockade on different B cell 
functions. It was observed that treating PBMCs with a specific Kv1.3 channel blocker 
resulted in decreased production of both total and PR3-ANCA specific IgG. This 
reduction was not the result of decreased proliferation of total B cells. Moreover, Kv1.3 
channel blockade resulted in a significant reduction of B cell cytokine production. This 
effect was particularly pronounced on the proinflammatory cytokines TNFα, IL2 and 
IFNγ, while the effect on IL10 was substantially less prominent. As such the TNFα/IL10 
ratio was significantly decreased with this treatment strategy, indicating that Kv1.3 
channel blockade may lead to a relative increase of B cells producing anti-inflammatory 
cytokines. While the effects we observed were on B cells, they may be the indirect result 
of decreased T cell activation as PBMC cultures were performed. While the stimulation 
in vitro was specifically aimed at B cells, T cell related effects cannot be excluded as for 
example T cell help is required in the production of IgG [81]. To fully elucidate the direct 
effect on B cells experiments with sorted B cells need to be performed. Furthermore 
it would be interesting to determine the effect of Shk-186 on B cell function in vivo 
by using animal models. Targeting both effector B and T cells makes Kv1.3 channel 
























In this thesis we demonstrate several alterations with regard to B cell function and 
phenotype in GPA patients compared to healthy controls. Moreover, these differences 
appear to be most pronounced in patients prior to disease relapse. B cell related markers, 
particularly the B cell subset distribution, are promising with regard to identification of 
patients that are at increased risk for disease relapse. Further improvement is needed 
as we have not identified a biomarker that can be directly applied in daily clinical 
practice. Future investigations could focus on measuring ANCA with newer methods 
and attempting to focus specifically on pathogenic ANCA. Finally, investigation of the 
regulatory function of B cells may be more informative than focusing on phenotypic 
identification. Especially the regulatory capacity of B cells beyond the production of 
IL10 requires more attention. 
References 
1. Ka l lenberg CGM: Advances in 
pathogenesis and treatment of ANCA-
associated vasculitis. Discov Med 2014, 
18:195–201.
2. van der Geld YM, Limburg PC, Kallenberg 
CG: Proteinase 3, Wegener’s autoantigen: 
from gene to antigen. J Leukoc Biol 2001, 
69:177–190.
3. Guilpain P, Servettaz A, Batteux F, Guillevin 
L, Mouthon L: Natural and disease 
associated anti-myeloperoxidase (MPO) 
autoantibodies. Autoimmun Rev 2008, 
7:421–425.
4. de Joode AAE, Sanders JSF, Rutgers A, 
Stegeman CA: Maintenance therapy in 
antineutrophil cytoplasmic antibody-
associated vasculitis: who needs what 
and for how long? Nephrol Dial Transplant 
2015, 30(suppl 1):i150–i158.
5. Robson J, Doll H, Suppiah R, Flossmann 
O, Harper L, Höglund P, Jayne D, Mahr A, 
Westman K, Luqmani R: Damage in the 
anca-associated vasculitides: long-term 
data from the European vasculitis study 
group (EUVAS) therapeutic trials. Ann 
Rheum Dis 2015, 74:177–184.
6. de Joode AAE, Sanders JSF, Stegeman 
CA: Renal survival in proteinase 3 and 
myeloperoxidase ANCA-associated 
systemic vasculitis. Clin J Am Soc Nephrol 
2013, 8:1709–1717.
7. Falk RJ, Terrell RS, Charles LA, Jennette 
JC: Anti -neutrophi l  c y toplasmic 
autoantibodies induce neutrophils to 
degranulate and produce oxygen radicals 
in vitro. Proc Natl Acad Sci USA 1990, 
87:4115–4119.
8. Kes senbrock K ,  K r umbholz  M, 
Schönermarck U, Back W, Gross WL, 
Werb Z, Gröne H-J, Brinkmann V, Jenne 
DE: Netting neutrophils in autoimmune 
small-vessel vasculitis. Nat Med 2009, 
15:623–625.
9. Savage CO, Pottinger BE, Gaskin G, 
Pusey CD, Pearson JD: Autoantibodies 
developing to myeloperoxidase and 
proteinase 3 in systemic vasculitis 
stimulate neutrophil cytotoxicity toward 
cultured endothelial cells. Am J Pathol 
1992, 141:335–342.
10. Xiao H, Heeringa P, Hu P, Liu Z, 
Zhao M, Aratani Y, Maeda N, Falk 
RJ, Jennet te JC: Antineutrophi l 
c y t o p l a s m i c  a u t o a n t i b o d i e s 
specific for myeloperoxidase cause 
glomerulonephritis and vasculitis in mice. 
J Clin Invest 2002, 110:955–963.
11. Little MA, Smyth CL, Yadav R, Ambrose 























Antineutrophil cytoplasm antibodies 
directed against myeloperoxidase 
augment leukocy te -microvascular 
interactions in vivo. Blood 2005, 
106:2050–2058.
12. Girard T, Mahr A, Noël LH, Cordier JF, 
Lesavre P, André MH, Guillevin L: Are 
antineutrophil cytoplasmic antibodies a 
marker predictive of relapse in Wegener’s 
granulomatosis? A prospective study. 
Rheumatology (Oxford) 2001, 40:147–151.
13. Tomasson G, Grayson PC, Mahr AD, 
Lavalley M, Merkel PA: Value of ANCA 
measurements during remission to 
predict a relapse of ANCA-associated 
vasculitis--a meta-analysis. Rheumatology 
(Oxford) 2012, 51:100–109.
14. Thai L-H, Charles P, Resche-Rigon 
M, Desseaux K, Guillevin L: Are anti-
proteinase-3 ANCA a useful marker 
of granulomatosis with polyangiitis 
(Wegener’s) relapses? Results of a 
retrospective study on 126 patients. 
Autoimmun Rev 2014, 13:313–318.
15. Kemna MJ, Damoiseaux J, Austen J, 
Winkens B, Peters J, van Paassen P, Cohen 
Tervaert JW: ANCA as a Predictor of 
Relapse: Useful in Patients with Renal 
Involvement But Not in Patients with 
Nonrenal Disease. J Am Soc Nephrol 2015, 
26:537–542.
16. Cohen Ter vaer t JW, Damoiseaux 
J :  A n t i n e u t ro p h i l  c y to p l a s m ic 
autoantibodies: how are they detected 
and what is their use for diagnosis, 
classification and follow-up? Clin Rev 
Allergy Immunol 2012, 43:211–219.
17. Roggenbuck D, Buettner T, Hoffmann 
L, Schmechta H, Reinhold D, Conrad 
K: High-sensi tiv i ty detec tion of 
autoantibodies against proteinase-3 by 
a novel third-generation enzyme-linked 
immunosorbent assay. Ann N Y Acad Sci 
2009, 1173:41–46.
18. Roth AJ, Ooi JD, Hess JJ, van Timmeren 
MM, Berg EA, Poulton CE, McGregor J, 
Burkart M, Hogan SL, Hu Y, Winnik W, 
Nachman PH, Stegeman CA, Niles J, 
Heeringa P, Kitching AR, Holdsworth S, 
Jennette JC, Preston GA, Falk RJ: Epitope 
specificity determines pathogenicity 
and detectability in ANCA-associated 
vasculitis. J Clin Invest 2013, 123:1773–
1783.
19. Cui Z, Zhao M, Segelmark M, 
Hellmark T: Natural autoantibodies to 
myeloperoxidase, proteinase 3, and the 
glomerular basement membrane are 
present in normal individuals. Kidney Int 
2010, 78:590–597.
20. van Timmeren MM, van der Veen BS, 
Stegeman CA, Petersen AH, Hellmark 
T, Collin M, Heeringa P: IgG glycan 
hydrolysis attenuates ANCA-mediated 
glomerulonephritis. J Am Soc Nephrol 
2010, 21:1103–1114.
21. Wuhrer M, Stavenhagen K, Koeleman CAM, 
Selman MHJ, Harper L, Jacobs BC, Savage 
COS, Jefferis R, Deelder AM, Morgan 
M: Skewed Fc glycosylation profiles of 
anti-proteinase 3 immunoglobulin G1 
autoantibodies from granulomatosis with 
polyangiitis patients show low levels of 
bisection, galactosylation, and sialylation. 
J Proteome Res 2015, 14:1657–1665.
22. Espy C, Morelle W, Kavian N, Grange 
P, Goulvestre C, Viallon V, Chéreau C, 
Pagnoux C, Michalski J-C, Guillevin L, 
Weill B, Batteux F, Guilpain P: Sialylation 
levels of anti-proteinase 3 antibodies 
are associated with the activity of 
granulomatosis with polyangi i t is 
(Wegener’s). Arthritis Rheum 2011, 
63:2105–2115.
23. Rodríguez-Pinto D: B cells as antigen 
presenting cells. Cellular Immunology 
2005, 238:67–75.
24. Bao Y, Cao X: The immune potential and 
immunopathology of cytokine-producing 
B cell subsets: a comprehensive review. J 
Autoimmun 2014, 55:10–23.
25. Menard LC, Minns LA, Darche S, Mielcarz 
DW, Foureau DM, Roos D, Dzierszinski F, 
Kasper LH, Buzoni-Gatel D: B cells amplify 
IFN-gamma production by T cells via 
























26. Barr TA, Brown S, Mastroeni P, Gray D: 
TLR and B cell receptor signals to B 
cells differentially program primary and 
memory Th1 responses to Salmonella 
enterica. J Immunol 2010, 185:2783–2789.
27. Mauri C, Bosma A: Immune Regulatory 
Function of B Cells. Annu Rev Immunol. 
2012, 30:221-41
28. Agematsu K, Hokibara S, Nagumo H, 
Komiyama A: CD27: a memory B-cell 
marker. Immunol Today 2000, 21:204–206.
29. Marie-Cardine A, Divay F, Dutot I, Green 
A, Perdrix A, Boyer O, Contentin N, Tilly H, 
Tron F, Vannier J-P, Jacquot S: Transitional 
B cells in humans: characterization 
and insight from B lymphocy te 
reconstitution after hematopoietic stem 
cell transplantation. Clin Immunol 2008, 
127:14–25.
30. Blair PA, Noreña LY, Flores-Borja F, Rawlings 
DJ, Isenberg DA, Ehrenstein MR, Mauri C: 
CD19(+)CD24(hi)CD38(hi) B cells exhibit 
regulatory capacity in healthy individuals 
but are functionally impaired in systemic 
Lupus Erythematosus patients. Immunity 
2010, 32:129–140.
31. Iwata Y, Matsushita T, Horikawa M, Dilillo 
DJ, Yanaba K, Venturi GM, Szabolcs PM, 
Bernstein SH, Magro CM, Williams AD, Hall 
RP, St Clair EW, Tedder TF: Characterization 
of a rare IL-10-competent B-cell subset in 
humans that parallels mouse regulatory 
B10 cells. Blood 2011, 117:530–541.
32. Lepse N, Abdulahad WH, Rutgers A, 
Kallenberg CGM, Stegeman CA, Heeringa 
P: Altered B cell balance, but unaffected B 
cell capacity to limit monocyte activation 
in anti-neutrophil cytoplasmic antibody-
associated vasculitis in remission. 
Rheumatology (Oxford) 2014, 53:1683–
1692.
33. Nanki T, Takada K, Komano Y, Morio 
T, Kanegane H, Nakajima A, Lipsky 
PE, Miyasaka N: Chemokine receptor 
expression and functional effects of 
chemokines on B cells: implication in the 
pathogenesis of rheumatoid arthritis. 
Arthritis Res Ther 2009, 11:R149.
34. Bohnhorst JO, Thoen JE, Natvig JB, 
Thompson KM: Significantly depressed 
percentage of CD27+ (memory) B cells 
among peripheral blood B cells in patients 
with primary Sjögren’s syndrome. Scand J 
Immunol 2001, 54:421–427.
35. Daien CI, Gailhac S, Mura T, Combe B, 
Hahne M, Morel J: High levels of memory 
B cells are associated with response to 
a first tumor necrosis factor inhibitor in 
patients with rheumatoid arthritis in a 
longitudinal prospective study. Arthritis 
Res Ther 2014, 16:R95.
36. Duddy M, Niino M, Adatia F, Hebert S, 
Freedman M, Atkins H, Kim HJ, Bar-Or 
A: Distinct effector cytokine profiles of 
memory and naive human B cell subsets 
and implication in multiple sclerosis. J 
Immunol 2007, 178:6092–6099.
37. Wilde B, Thewissen M, Damoiseaux J, 
Knippenberg S, Hilhorst M, van Paassen P, 
Witzke O, Cohen Tervaert JW: Regulatory 
B cells in ANCA-associated vasculitis. Ann 
Rheum Dis 2013, 72:1416-9
38. Aybar LT, McGregor JG, Hogan SL, Hu 
Y, Mendoza CE, Brant EJ, Poulton CJ, 
Henderson CD, Falk RJ, Bunch DO: 
Reduced CD5(+) CD24(hi) CD38(hi) 
and interleukin-10(+) regulatory B cells 
in active anti-neutrophil cytoplasmic 
autoantibody-associated vasculitis permit 
increased circulating autoantibodies. Clin 
Exp Immunol 2015, 180:178–188.
39. Maseda D, Smith SH, DiLillo DJ, Bryant 
JM, Candando KM, Weaver CT, Tedder 
TF: Regulatory B10 cells differentiate into 
antibody-secreting cells after transient 
IL-10 production in vivo. J Immunol 2012, 
188:1036–1048.
40. Bunch DO, McGregor JG, Khandoobhai 
NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, 
Poulton CJ, Berg EA, Falk RJ, Nachman PH: 
Decreased CD5+ B Cells in Active ANCA 
Vasculitis and Relapse after Rituximab. 
Clin J Am Soc Nephrol 2013, 8:382–391.
41. Bunch DO, Mendoza CE, Aybar LT, Kotzen 
ES, Colby KR, Hu Y, Hogan SL, Poulton 
CJ, Schmitz JL, Falk RJ, Nachman PH, 























relapse risk from B cell phenotype: 
decreased CD5+ B cells portend a shorter 
time to relapse after B cell depletion in 
patients with ANCA-associated vasculitis. 
Ann Rheum Dis 2015, 74:1784-6
42. Gary-Gouy H, Harriague J, Bismuth G, 
Platzer C, Schmitt C, Dalloul AH: Human 
CD5 promotes B-cell survival through 
stimulation of autocrine IL-10 production. 
Blood 2002, 100:4537–4543.
43. Lundy SK: Killer B lymphocytes: the 
evidence and the potential. Inflamm Res 
2009, 58:345–357.
44. Matsumoto M, Baba A, Yokota T, Nishikawa 
H, Ohkawa Y, Kayama H, Kallies A, Nutt SL, 
Sakaguchi S, Takeda K, Kurosaki T, Baba Y: 
Interleukin-10-producing plasmablasts 
exert regulatory function in autoimmune 
inflammation. Immunity 2014, 41:1040–1051.
45. de Masson A, Bouaziz J-D, Le Buanec H, 
Robin M, O’Meara A, Parquet N, Rybojad 
M, Hau E, Monfort J-B, Branchtein M, 
Michonneau D, Dessirier V, Sicre de 
Fontbrune F, Bergeron A, Itzykson R, 
Dhédin N, Bengoufa D, Peffault de Latour 
R, Xhaard A, Bagot M, Bensussan A, 
Socié G: CD24hiCD27+ and plasmablast-
like regulatory B cells in human chronic 
graft-versus-host disease. Blood 2015, 
125:1830–1839.
46. Simon Q, Pers J-O, Cornec D, Le 
Pottier L, Mageed RA, Hillion S: In-
depth characterization of CD24(high)
CD38(high) transitional human B  cells 
reveals different regulatory profiles. J 
Allergy Clin Immunol 2015.
47. Bouaziz J-D, Calbo S, Maho-Vaillant 
M, Saussine A, Bagot M, Bensussan A, 
Musette P: IL-10 produced by activated 
human B cells regulates CD4(+) T-cell 
activation in vitro. Eur J Immunol 2010, 
40:2686–2691.
48. Ray A, Wang L, Dit tel BN: IL-10-
independent regulatory B-cell subsets 
and mechanisms of action. Int Immunol 
2015, 27:531-6
49. Ray A, Basu S, Williams CB, Salzman NH, 
Dittel BN: A Novel IL-10-Independent 
Regulatory Role for B Cells in Suppressing 
Autoimmunity by Maintenance of 
Regulatory T Cells via GITR Ligand. 
Journal of Immunology (Baltimore, Md: 
1950) 2012, 188:3188–3198.
50. Francisco LM, Salinas VH, Brown KE, 
Vanguri VK, Freeman GJ, Kuchroo 
VK, Sharpe AH: PD-L1 regulates the 
development, maintenance, and function 
of induced regulatory T cells. J Exp Med 
2009, 206:3015–3029.
51. Khan AR, Hams E, Floudas A, Sparwasser T, 
Weaver CT, Fallon PG: PD-L1hi B cells are 
critical regulators of humoral immunity. 
Nat Commun 2015, 6:5997.
52. Shen P, Roch T, Lampropoulou V, O’Connor 
RA, Stervbo U, Hilgenberg E, Ries S, Dang 
VD, Jaimes Y, Daridon C, Li R, Jouneau L, 
Boudinot P, Wilantri S, Sakwa I, Miyazaki 
Y, Leech MD, McPherson RC, Wirtz S, 
Neurath M, Hoehlig K, Meinl E, Grützkau 
A, Grün JR, Horn K, Kühl AA, Dörner T, 
Bar-Or A, Kaufmann SHE, Anderton 
SM, et al.: IL-35-producing B cells are 
critical regulators of immunity during 
autoimmune and infectious diseases. 
Nature 2014, 507:366–370.
53. Kerkman PF, Rombouts Y, van der Voort 
EIH, Trouw LA, Huizinga TWJ, Toes REM, 
Scherer HU: Circulating plasmablasts/
plasmacells as a source of anticitrullinated 
protein antibodies in patients with 
rheumatoid arthritis. Ann Rheum Dis 2013, 
72:1259–1263.
54. Heine G, Drozdenko G, Grün JR, Chang 
H-D, Radbruch A, Worm M: Autocrine IL-
10 promotes human B-cell differentiation 
into IgM- or IgG-secreting plasmablasts. 
Eur J Immunol 2014, 44:1615–1621.
55. Stone JH, Merkel PA, Spiera R, Seo P, 
Langford CA, Hoffman GS, Kallenberg 
CGM, St Clair EW, Turkiewicz A, Tchao NK, 
Webber L, Ding L, Sejismundo LP, Mieras K, 
Weitzenkamp D, Ikle D, Seyfert-Margolis V, 
Mueller M, Brunetta P, Allen NB, Fervenza 
FC, Geetha D, Keogh KA, Kissin EY, Monach 
PA, Peikert T, Stegeman C, Ytterberg SR, 
Specks U, RAVE-ITN Research Group: 























ANCA-associated vasculitis. N Engl J Med 
2010, 363:221–232.
56. Jones RB, Furuta S, Tervaert JWC, Hauser 
T, Luqmani R, Morgan MD, Peh CA, 
Savage CO, Segelmark M, Tesar V, van 
Paassen P, Walsh M, Westman K, Jayne 
DR, European Vasculitis Society (EUVAS): 
Rituximab versus cyclophosphamide in 
ANCA-associated renal vasculitis: 2-year 
results of a randomised trial. Ann Rheum 
Dis 2015, 74:1178–1182.
57. Guillevin L, Pagnoux C, Karras A, Khouatra 
C, Aumaître O, Cohen P, Maurier F, 
Decaux O, Ninet J, Gobert P, Quémeneur 
T, Blanchard-Delaunay C, Godmer P, 
Puéchal X, Carron P-L, Hatron P-Y, Limal N, 
Hamidou M, Ducret M, Daugas E, Papo T, 
Bonnotte B, Mahr A, Ravaud P, Mouthon L, 
French Vasculitis Study Group: Rituximab 
versus azathioprine for maintenance in 
ANCA-associated vasculitis. N Engl J Med 
2014, 371:1771–1780.
58. Roberts DM, Jones RB, Smith RM, 
Alberici F, Kumaratne DS, Burns S, Jayne 
DRW: Immunoglobulin G replacement 
for the treatment of in fec tive 
complications of rituximab-associated 
hypogammaglobulinemia in autoimmune 
disease: a case series. J Autoimmun 2015, 
57:24–29.
59. Gorbacheva V, Ayasoufi K, Fan R, Baldwin 
WM, Valujskikh A: B cell activating factor 
(BAFF) and a proliferation inducing ligand 
(APRIL) mediate CD40-independent help 
by memory CD4 T cells. Am J Transplant 
2015, 15:346–357.
60. Thien M, Phan TG, Gardam S, Amesbury 
M, Basten A, Mackay F, Brink R: Excess 
BAFF rescues self-reactive B cells from 
peripheral deletion and allows them to 
enter forbidden follicular and marginal 
zone niches. Immunity 2004, 20:785–798.
61. Krumbholz M, Specks U, Wick M, Kalled 
SL, Jenne D, Meinl E: BAFF is elevated 
in serum of patients with Wegener’s 
granulomatosis. J Autoimmun 2005, 
25:298–302.
62. Mueller A, Brieske C, Schinke S, Csernok 
E, Gross WL, Hasselbacher K, Voswinkel 
J, Holl-Ulrich K: Plasma cells within 
granulomatous inflammation display signs 
pointing to autoreactivity and destruction 
in granulomatosis with polyangiitis. 
Arthritis Res Ther 2014, 16:R55.
63. Zhao Y, Odell E, Choong LM, Barone F, 
Fields P, Wilkins B, Tungekar FM, Patel P, 
Sanderson JD, Sangle S, D’Cruz D, Spencer 
J: Granulomatosis with polyangiitis 
involves sustained mucosal inflammation 
that is rich in B-cell survival factors and 
autoantigen. Rheumatology (Oxford) 
2012, 51:1580–1586.
64. Holden NJ, Williams JM, Morgan MD, 
Challa A, Gordon J, Pepper RJ, Salama AD, 
Harper L, Savage COS: ANCA-stimulated 
neutrophils release BLyS and promote B 
cell survival: a clinically relevant cellular 
process. Ann Rheum Dis 2011, 70:2229–
2233.
65. Navarra SV, Guzmán RM, Gallacher AE, 
Hall S, Levy RA, Jimenez RE, Li EK-M, 
Thomas M, Kim H-Y, León MG, Tanasescu 
C, Nasonov E, Lan J-L, Pineda L, Zhong 
ZJ, Freimuth W, Petri MA, BLISS-52 Study 
Group: Efficacy and safety of belimumab 
in patients with active systemic lupus 
erythematosus: a randomised, placebo-
controlled, phase 3 trial. Lancet 2011, 
377:721–731.
66. Furie R, Petri M, Zamani O, Cervera R, 
Wallace DJ, Tegzová D, Sanchez-Guerrero 
J, Schwarting A, Merrill JT, Chatham WW, 
Stohl W, Ginzler EM, Hough DR, Zhong ZJ, 
Freimuth W, van Vollenhoven RF, BLISS-76 
Study Group: A phase III, randomized, 
placebo-controlled study of belimumab, 
a monoclonal antibody that inhibits B 
lymphocyte stimulator, in patients with 
systemic lupus erythematosus. Arthritis 
Rheum 2011, 63:3918–3930.
67. Genovese MC, Bojin S, Biagini IM, Mociran 
E, Cristei D, Mirea G, Georgescu L, Sloan-
Lancaster J: Tabalumab in rheumatoid 
arthritis patients with an inadequate 
response to methotrexate and naive to 
biologic therapy: a phase II, randomized, 
























68. Lenert A, Lenert P: Current and emerging 
treatment options for ANCA-associated 
vasculitis: potential role of belimumab 
and other BAFF/APRIL targeting agents. 
Drug Des Devel Ther 2015, 9:333–347.
69. Scholz JL, Crowley JE, Tomayko MM, 
Steinel N, O’Neill PJ, Quinn WJ, Goenka 
R, Miller JP, Cho YH, Long V, Ward C, 
Migone T-S, Shlomchik MJ, Cancro MP: 
BLyS inhibition eliminates primary B cells 
but leaves natural and acquired humoral 
immunity intact. Proc Natl Acad Sci USA 
2008, 105:15517–15522.
70. Benson MJ, Dillon SR, Castigli E, Geha RS, 
Xu S, Lam K-P, Noelle RJ: Cutting edge: 
the dependence of plasma cells and 
independence of memory B cells on BAFF 
and APRIL. J Immunol 2008, 180:3655–3659.
71. Langford CA, Monach PA, Specks U, Seo 
P, Cuthbertson D, McAlear CA, Ytterberg 
SR, Hoffman GS, Krischer JP, Merkel PA, 
Vasculitis Clinical Research Consortium: An 
open-label trial of abatacept (CTLA4-IG) 
in non-severe relapsing granulomatosis 
with polyangiitis (Wegener’s). Ann Rheum 
Dis 2014, 73:1376–1379.
72. Scarsi M, Paolini L, Ricotta D, Pedrini A, 
Piantoni S, Caimi L, Tincani A, Airò P: 
Abatacept reduces levels of switched 
memory B cells, autoantibodies, and 
immunoglobulins in patients with 
rheumatoid arthritis. J Rheumatol 2014, 
41:666–672.
73. Roll P, Muhammad K, Schumann M, 
Kleinert S, Einsele H, Dörner T, Tony H-
P: In vivo effects of the anti-interleukin-6 
receptor inhibitor tocilizumab on the B 
cell compartment. Arthritis Rheum 2011, 
63:1255–1264.
74. Snir A, Kessel A, Haj T, Rosner I, Slobodin 
G, Toubi E: Anti-IL-6 receptor antibody 
(tocilizumab): a B cell targeting therapy. 
Clin Exp Rheumatol 2011, 29:697–700.
75. Burmester GR, Rigby WF, van Vollenhoven 
RF, Kay J, Rubbert-Roth A, Kelman A, 
Dimonaco S, Mitchell N: Tocilizumab in 
early progressive rheumatoid arthritis: 
FUNCTION, a randomised controlled 
trial. Ann Rheum Dis 2015.
76. Loricera J, Blanco R, Hernández JL, 
Castañeda S, Mera A, Pérez-Pampín 
E, Peiró E, Humbría A, Calvo-Alén J, 
Aurrecoechea E, Narváez J, Sánchez-
Andrade A, Vela P, Díez E, Mata C, Lluch 
P, Moll C, Hernández Í, Calvo-Río V, 
Ortiz-Sanjuán F, González-Vela C, Pina T, 
González-Gay MÁ: Tocilizumab in giant 
cell arteritis: Multicenter open-label 
study of 22 patients. Semin Arthritis 
Rheum 2015, 44:717–723.
77. Wulf f H, Knaus H-G, Pennington M, 
Chandy KG: K+ channel expression during 
B cell differentiation: implications for 
immunomodulation and autoimmunity. J 
Immunol 2004, 173:776–786.
78. Kindler V, Zubler RH: Memory, but not 
naive, peripheral blood B lymphocytes 
differentiate into Ig-secreting cells after 
CD40 ligation and costimulation with IL-4 
and the differentiation factors IL-2, IL-10, 
and IL-3. J Immunol 1997, 159:2085–2090.
79. Beeton C, Pennington MW, Wulff H, 
Singh S, Nugent D, Crossley G, Khaytin 
I, Calabresi PA, Chen C-Y, Gutman GA, 
Chandy KG: Targeting effector memory 
T cells with a selective peptide inhibitor of 
Kv1.3 channels for therapy of autoimmune 
diseases. Mol Pharmacol 2005, 67:1369–
1381.
80. Hyodo T, Oda T, Kikuchi Y, Higashi K, 
Kushiyama T, Yamamoto K, Yamada M, 
Suzuki S, Hokari R, Kinoshita M, Seki S, 
Fujinaka H, Yamamoto T, Miura S, Kumagai 
H: Voltage-gated potassium channel 
Kv1.3 blocker as a potential treatment for 
rat anti-glomerular basement membrane 
glomerulonephritis. Am J Physiol Renal 
Physiol 2010, 299:F1258–1269.
81. Duffy D, Yang C-P, Heath A, Garside P, Bell 
EB: Naive T-cell receptor transgenic T cells 
help memory B cells produce antibody. 
Immunology 2006, 119:376–384.
163

